Betterlife talks up BETR-001 benefits

Executive Summary

• Betterlife Pharma highlights the advantages of its lead candidate, BETR-001, a non-hallucinogenic LSD derivative, contrasting it with recent negative Phase 2 results for LSD microdosing in depression.
• The company emphasizes that BETR-001 maintains neuroplastogenic effects at full doses without inducing hallucinations or tolerance, allowing for chronic administration and self-administration.
• BETR-001 is currently in IND-enabling studies, with plans to file an Investigational New Drug (IND) application and initiate human clinical trials in the second half of 2026.

Key Details

• Product Profile (BETR-001):
  • Non-hallucinogenic even at high doses.
  • Does not induce tolerance with repeated use, enabling chronic or repeated dosing.
  • Unregulated and non-controlled, allowing for self-administration.
  • Synthesis patent held by Betterlife; composition and method of use patent pending (coverage until ~2042).
• Development Timeline:
  • Currently completing last remaining IND-enabling studies.
  • Target to file IND and begin human clinical trials by H2 2026.
• Indications:
  • Initial scope: Traumatic Brain Injury (TBI), cluster headaches, and migraine.
  • Future potential: Broad range of psychiatric disorders.
• Strategic Context:
  • Company is seeking strategic alternatives for a separate drug candidate for viral infections.
  • CEO Dr. Ahmad Doroudian notes that BETR-001 avoids the need for specialized clinic monitoring (8-12 hours) required for full-dose psychedelics.

Notable Quotes

• "The importance of being able to give full doses of BETR-001 without hallucinations cannot be overemphasized. Microdosing of psychedelics is often touted as the path forward to avoid the hallucinations of psychedelics full dosing and the need for treatment in specialized clinics with monitoring under special treatment protocols, which require in-clinic time of eight to 12 hours. BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations." — Dr. Ahmad Doroudian, CEO
• "We are completing the last remaining BETR-001 IND-enabliing studies and plan to file the IND and begin human clinical trials by H2 2026." — Dr. Ahmad Doroudian, CEO